Literature DB >> 21569126

Differential effects of cyclosporine and tacrolimus on arterial function.

Felix Seibert1, Carolin Behrendt, Sven Schmidt, Markus van der Giet, Walter Zidek, Timm H Westhoff.   

Abstract

Cardiovascular complications are the leading cause of death in renal transplant recipients and constitute one of the leading causes of graft failure. Calcineurin inhibitors (CNI) induce an acceleration of atherosclerotic processes in the arterial wall. There are conflicting data whether cyclosporine A (CsA) and tacrolimus (Tac) differ in their deleterious effects on arterial stiffening. The present study combines several measurement techniques to provide a global and reliable assessment of the differential effects of CNI on the gold-standard parameters of arterial function. Pulse wave analysis was performed by the SphygmoCor (AtCor(®) ), HEM-9000AI (Omron(®) ), and CR-2000 device (Hypertension Diagnostics(®) ) in 56 stable renal transplant recipients (29 CsA, 27 Tac). Groups were homogeneous for age, gender, body mass index, time on dialysis prior to transplantation, and graft function. Whereas systolic and diastolic blood pressure, central aortic blood pressure, cardiac index, large and small artery compliance index (C(1) and C(2) ), and pulse wave velocity did not significantly differ between CsA and Tac, augmentation index (AI(75) ) was significantly lower in patients treated with Tac. This finding was consistent as assessed by two different measurement systems (P < 0.05). Compared to CsA, Tac has a favorable impact on augmentation index, a strong independent predictor for cardiovascular mortality.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569126     DOI: 10.1111/j.1432-2277.2011.01265.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  8 in total

1.  A spontaneous coronary arterial dissection associated with a calcineurin inhibitor.

Authors:  Dermot Henry Mallon; Daniel McKenzie; Mark Dayer
Journal:  BMJ Case Rep       Date:  2012-07-10

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 3.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

Review 4.  Role of hypertension in kidney transplant recipients.

Authors:  Charalampos Loutradis; Pantelis Sarafidis; Smaragdi Marinaki; Miriam Berry; Richard Borrows; Adnan Sharif; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2021-05-04       Impact factor: 3.012

5.  Assessments of arterial stiffness and endothelial function using pulse wave analysis.

Authors:  Lee Stoner; Joanna M Young; Simon Fryer
Journal:  Int J Vasc Med       Date:  2012-05-14

6.  Comparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta.

Authors:  Ashok Jadhav; Venkat Gopalakrishnan; Ahmed Shoker
Journal:  Adv Pharmacol Sci       Date:  2013-06-18

7.  Cyclosporin A Aggravates Calcification of Vascular Smooth Muscle Cells Under High-Glucose Conditions with a Calcifying Medium.

Authors:  Dae Hee Kim; Keon Cheol Lee; Sang Youb Han
Journal:  Ann Transplant       Date:  2018-02-13       Impact factor: 1.530

8.  A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity.

Authors:  Gerold Thölking; Katharina Schütte-Nütgen; Julia Schmitz; Alexandros Rovas; Maximilian Dahmen; Joachim Bautz; Ulrich Jehn; Hermann Pavenstädt; Barbara Heitplatz; Veerle Van Marck; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.